Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2011

View Archived Issues

Viamet Pharmaceuticals' antifungals show promise in models of candidiasis and dermatophytosis

Preclinical and clinical data presented on AZD-5847 for tuberculosis

Takeda initiates phase I/II brentuximab vedotin study in Japan

Dosing complete in phase I trial of Antisense Therapeutics drug

Portuguese study identifies new biomarker for prognosis of ovarian cancer

Preclinical data support first-in-human trial of NBTXR-3

Merck Sharp & Dohme describes mode of action of antibacterial antibody CS-D7

SAVE-ONCO trial assesses semuloparin for thromboprophylaxis in patients with cancer

New York University prepares new anti-infective compounds

Kalypsys discloses novel histamine H4 receptor antagonists

New cysteine and cystine prodrugs presented by Promentis Pharmaceuticals

Vertex Pharmaceuticals launches Incivek in Canada

GSK provides funding for cancer research program

Researchers at Astellas synthesize new serotonin 5-HT2C receptor agonists

New muscarinic acetylcholine M1 receptor allosteric agonists claimed

Phase II study starts for Aduro BioTech's pancreatic cancer vaccines

FDA issues warning regarding leukemia drug Sprycel

UCSF receives NIH grant for antimalarial research

BioSante Pharmaceuticals reports phase III safety data on LibiGel

GlycoMimetics and Pfizer collaborate on GMI-1070 in sickle cell disease

Lilly files for additional approval for Strattera in Japan

Bayer and Onyx Pharmaceuticals restructure oncology collaboration

EMA recommends new orphan designation for 4SC-201

Kancera subsidiary discovers potent inhibitors of target schistosome protein

EMA confirms design of Intercell's planned phase II/III trial of Pseudomonas aeruginosa vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...